OMERS Infrastructure, Goldman Sachs Asset Management and AXA IM Alts have agreed to acquire Amedes, a provider of medical diagnostics services in Germany, Belgium and Austria, from current investor Antin Infrastructure Partners.
Amedes has ows over 75 laboratories and specialty medicine sites across Germany, Belgium and Austria.
“OMERS is pleased to be backing amedes and its management team in its continued pursuit of medical excellence. Amedes is our fourth infrastructure investment in Germany, which continues to be a core region of interest to us. We welcome the opportunity to increase our exposure to this market and the lab diagnostics sector, as it further diversifies our portfolio and contributes to the generation of steady returns for our pension plan members. We look forward to working alongside our investment partners to support amedes as it continues to perform its essential role in the communities in which it is active,” said Philippe Busslinger, Senior Managing Director and Head of Europe, OMERS Infrastructure.
Philippe Camu, Global Co-Head of the Infrastructure business within Goldman Sachs Asset Management said: “Amedes is a leader in European diagnostics, providing essential services for the detection and prevention of diseases. Our investment thesis is based on the resiliency of the business, driven by a stable regulatory framework as well as by strong secular trends in the sector.”
Matteo Botto Poala, Managing Director in the Infrastructure business within Goldman Sachs Asset Management, added “We are excited to work with Amedes’ management team to accelerate growth through innovation, commercial and operational initiatives, and acquisitions.”
Mark Gilligan, Head of Infrastructure Equity at AXA IM Alts, said: “Our investment into Amedes alongside Goldman Sachs Asset Management and OMERS Infrastructure, follows our June 2021 investment in Stockholm Exergi and aligns with our strategy of assembling a premier portfolio of core through to core plus European infrastructure businesses. Through its superb network of medical laboratories and clinics across Germany, Belgium and Austria, it possesses that most critical thing we seek as infrastructure investors – essentiality. We share our partners’ vision for the growth of the firm and look forward to working with management as it continues to deliver world-class cost-effective services to its customers and patients.”